There has been many exciting investments and advancements in the field, such as Atavistik Bio raising an additional $40 million to advance their small molecule therapeutics and Servier and Base4 expanding their partnership to accelerate development of neuroscience drugs. However, the discovery of potent RNA targeting small molecules is plagued by limited robust assays and screening methods for understanding the RNA target structure as well as the mechanism of action of the small molecule drugs.

Hence, this August the 2nd RNA Assay Development & Screening Summit returns to Boston as the first and only industry dedicated event on developing sensitive, and reproducible assay and screening methods. With 70% brand new speaker faculty from key stakeholder companies as well as new companies entering the field, including the likes of AstraZeneca, Arrakis Therapeutics, Molecure, Wayfinder Biosciences, Biogen and more, access the latest strategies for developing reproducible and sensitive assay and screening methods.

Download the free brochure or book your place now, early birds are still available!